Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024 [Yahoo! Finance]
Rani Therapeutics Holdings, Inc. - Class A (RANI)
Company Research
Source: Yahoo! Finance
biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it will present clinical and preclinical and data on the RaniPill ® capsule, the company's oral delivery platform, at Digestive Disease Week ® (DDW) taking place both virtually and in-person on May 18-21, 2024 in Washington, DC. Details of the presentations are as follows: Abstract Title: An Orally Administered Robotic Pill (RP) Reliably and Safely Delivers an Ustekinumab Biosimilar RT-111 with High Bioavailability Relative to Subcutaneous (SC) Ustekinumab in Healthy Human Participants Session Type: Late-Breaking Oral Presentation Session Title: IMIBD Late Breakers and Innovations in IBD Session Date & Time: May 19, 2024 from 2:00 – 3:30 EDT Presentation Time: 3:00 PM to 3:15 PM EDT Session Number: Presenting Author: Jacques Van Dam, MD, PhD Abstract Title: Orally-Administered Ustekinumab Biosimilar RT-111 Delivered Via a Robotic Pill Yields Bioavailability Comparable to
Show less
Read more
Impact Snapshot
Event Time:
RANI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RANI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RANI alerts
High impacting Rani Therapeutics Holdings, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
RANI
News
- Rani Therapeutics to Participate in May Investor ConferencesGlobeNewswire
- Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target raised by analysts at BTIG Research from $7.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024GlobeNewswire
- Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) had its price target raised by analysts at HC Wainwright from $12.00 to $13.00. They now have a "buy" rating on the stock.MarketBeat
- Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
RANI
Earnings
- 5/6/24 - Miss
RANI
Sec Filings
- 5/30/24 - Form 4
- 5/30/24 - Form 4
- 5/30/24 - Form 4
- RANI's page on the SEC website